ADAM17 cleaves transmembrane TNF into its soluble form. Secreted TNF levels correlated with poor patient outcomes in the devastating cancer, hepatocellular carcinoma (HCC). HCC is the most common liver cancer worldwide. In this application we are examining targeting ADAM17, TNF, and receptors of TNF with cutting edge techniques to determine if these targets are viable in HCC.